GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (CHIX:COPNz) » Definitions » Price-to-Free-Cash-Flow

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Price-to-Free-Cash-Flow : 48.65 (As of May. 11, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cosmo Pharmaceuticals NV Price-to-Free-Cash-Flow?

As of today (2024-05-11), Cosmo Pharmaceuticals NV's share price is CHF70.50. Cosmo Pharmaceuticals NV's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was CHF1.45. Hence, Cosmo Pharmaceuticals NV's Price-to-Free-Cash-Flow Ratio for today is 48.65.

The historical rank and industry rank for Cosmo Pharmaceuticals NV's Price-to-Free-Cash-Flow or its related term are showing as below:

CHIX:COPNz' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 21.74   Med: 201.19   Max: 738.52
Current: 49.41

During the past 13 years, Cosmo Pharmaceuticals NV's highest Price-to-Free-Cash-Flow Ratio was 738.52. The lowest was 21.74. And the median was 201.19.

CHIX:COPNz's Price-to-Free-Cash-Flow is ranked worse than
74.6% of 500 companies
in the Drug Manufacturers industry
Industry Median: 22.74 vs CHIX:COPNz: 49.41

Cosmo Pharmaceuticals NV's Free Cash Flow per Share for the six months ended in Jun. 2023 was CHF0.49. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was CHF1.45.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Cosmo Pharmaceuticals NV was 183.00% per year.

During the past 13 years, Cosmo Pharmaceuticals NV's highest 3-Year average Free Cash Flow per Share Growth Rate was 143.30% per year. The lowest was -19.10% per year. And the median was 26.60% per year.


Cosmo Pharmaceuticals NV Price-to-Free-Cash-Flow Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV Price-to-Free-Cash-Flow Chart

Cosmo Pharmaceuticals NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 232.24 259.29 39.31

Cosmo Pharmaceuticals NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 259.29 - 39.31 -

Competitive Comparison of Cosmo Pharmaceuticals NV's Price-to-Free-Cash-Flow

For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosmo Pharmaceuticals NV's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cosmo Pharmaceuticals NV's Price-to-Free-Cash-Flow falls into.



Cosmo Pharmaceuticals NV Price-to-Free-Cash-Flow Calculation

Cosmo Pharmaceuticals NV's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=70.50/1.449
=48.65

Cosmo Pharmaceuticals NV's Share Price of today is CHF70.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo Pharmaceuticals NV's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was CHF1.45.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Cosmo Pharmaceuticals NV  (CHIX:COPNz) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Cosmo Pharmaceuticals NV Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosmo Pharmaceuticals NV (CHIX:COPNZ) Business Description

Traded in Other Exchanges
Address
Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Headlines

No Headlines